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IL-17 is a cytokine with powerful proinﬂammatory activity. Production of IL-17 is abnormally increased in patients with systemic
lupus erythematosus (SLE), a multiorgan chronic autoimmune disease. In patients with SLE, CD3+CD4−CD8− (double negative)
T cells are an important source of IL-17. IL-17 produced by double negative and CD4 T cells participates in the pathogenesis
of the disease. IL-17-producing T cells are present in the kidneys of patients with lupus nephritis. IL-17 increased production in
patients with SLE can amplify the immune response by increasing target organ inﬂammation and damage and by augmenting the
production of antibodies by B cells.
1.Introduction
Systemic lupus erythematosus (SLE) is an autoimmune dis-
order that appears in genetically prone individuals triggered
by ill-deﬁned environmental factors [1]. Patients with SLE
develop an immune response against numerous, mostly
intracellular self-antigens. This chronic response alters the
function of the immune system and releases self-antigens
that along with autoantibodies form immune complexes
that deposit in susceptible vascular beds, mostly in skin,
joints, and renal glomeruli. Immune complex deposition
causes local inﬂammation and tissue damage that probably
amplify the autoimmune response creating thus a vicious
cycle.
Cytokines are intimately involved in SLE pathogenesis.
They contribute to the underlying immune dysfunction and
to immune-mediated events that damage target organs. IL-
17 is a cytokine with powerful inﬂammatory properties.
Recent evidence suggests that it is involved in the patho-
genesis of SLE. In this paper, we discuss the evidence that
links IL-17 to SLE in both human and animal models.
Data indicates that IL-17-driven inﬂammation ampliﬁes
SLE-induced tissue damage and contributes to tolerance
breakdown in SLE patients.
2.Interleukin-17
Interleukin (IL)-17 is an ancient cytokine intimately related
withepithelia—particularlywiththeintestinalmucosa[2,3].
Its main receptor, IL-17RA, is broadly expressed on epithelial
and endothelial cells as well as on immune cells [4–6].
It is produced by several cell types including activated T
cell subsets (CD4+,C D 8 +,a n dT C R - αβ CD4− CD8−,T C R -
γδ), natural killer cells, and neutrophils [7]. IL-17 plays an
essential role in the immune response against bacteria and
fungi [8].
IL-17 has pro-inﬂammatory capacities exerted through
its ability to induce secretion of chemokines such as IL-8,
monocyte chemoattractant protein-1 (MCP-1), and growth-
related oncogene protein-α, which recruit monocytes and
neutrophils [9–12]. IL-17 also facilitates T cell activation
and inﬁltration into tissues by upregulating the expression
ofintercellularadhesionmolecule-1(ICAM-1)andampliﬁes
the immune response by inducing the production of IL-6,
prostaglandin E2, granulocyte-macrophage colony stimulat-
ing factor (GM-CSF), and granulocyte colony stimulating
factor [13–15]. Additionally, IL-17 acts synergistically with
other cytokines, particularly IL-1β, tumor necrosis factor





Figure 1: The IL-17 response is ampliﬁed in SLE. Nucleic acid-containing immune complexes and other inﬂammatory stimuli (e.g.,
cytokines) induce the production of pro-inﬂammatory cytokines by dendritic cells. These factors, along with others not yet identiﬁed,
favor the generation of pro-inﬂammatory IL-17-producing T cell subsets (i.e., TH17 and DN T cells) able to migrate to target organs and
inﬂict damage. Produced IL-17 ampliﬁes the inﬂammatory response and stimulates other cell types (e.g., B cells).
IL-17-producing cells have been recently implicated in
the pathogenesis of a wide range of inﬂammatory and
autoimmunediseasesincludingpsoriasis,rheumatoidarthri-
tis (RA) [17, 18], inﬂammatory bowel disease (IBD) [19],
systemic sclerosis [20], and systemic lupus erythematosus
(SLE) [21, 22].
3. IL-17 Productionin SLE
Evidence indicates that production of IL-17 is abnormally
high in patients with SLE. Its levels are increased in SLE
sera [23] and correlate with SLE disease activity [22, 24].
Moreover, the frequency of IL-17-producing T cells is
increased in the peripheral blood of patients with SLE [21,
22, 25].
A signiﬁcant fraction of the IL-17 produced in
SLE patients derives from double negative (DN) TCR-
αβ
+CD4−CD8− T cells [21]. DN T cells represent a small T
cell subset in healthy individuals. These cells are expanded
in peripheral blood of SLE patients and produce pro-
inﬂammatory chemokines and cytokines including IL-17,
IFN-γ,a n dI L - 1 β [26]. Support for their pathogenic role
derives from the fact that IL-17-producing T cells have been
observed in kidneys of patients with lupus nephritis [21, 27],
among inﬁltrates rich in DN T cells [21].
Apart from its direct pro-inﬂammatory activity, the
eﬀects of IL-17 in other cell types may contribute to SLE
pathogenesis.IncreasedproductionoftotalIgG,anti-dsDNA
IgG, and IL-6 by peripheral blood mononuclear cells of
patients with lupus nephritis was observed when they were
cultured in the presence of IL-17 [28]. These ﬁndings suggest
that IL-17 may participate in the activation of B cells in
patients with SLE.
IL-17 production is also high in mice aﬀected by lupus-
like diseases [29]. An abnormally high fraction of T cells
from MRL/lpr mice produce IL-17 [29]. In these mice, as
in patients with SLE, DN T cells are an important source of
IL-17. Interestingly, lymph node cells derived from MRL/lpr
micewereabletocauseglomerulonephritiswhentransferred
into lymphocyte-deﬁcient Rag−/− mice. The eﬀect depended
on their prestimulation with IL-23, a cytokine known to
stimulate IL-17 production in humans and mice [29]. IL-17,
along with IL-13 and IFN-γ, is the main cytokine produced
by inﬁltrating T cells in nephritic kidneys of MRL/lpr mice
[29, 30].
In SNF1 mice (New Zealand Black x SWR F1), spleen
cells produce signiﬁcantly higher amounts of IL-17 than
spleen cells from control mice when cultured in the presence
of nucleosomes, a known lupus autoantigen [31]. In these
mice as in the MRL/lpr,I L - 1 7 - p r o d u c i n gTc e l l sa r ed e t e c t e d
in kidneys aﬀected by nephritis. Interestingly, clinical disease
improved along with decreased IL-17 production in mice
treated with a tolerating regime induced with a histone-
derived peptide [31], or with nasal administration of anti-
CD3 [32].
The BXD2 mouse, a model that spontaneously develops
arthritis, glomerulonephritis, and autoantibodies [33], has
highIL-17levelsinserumaswellasincreasednumbersofIL-
17+ cellsinthespleen[34].Accordingly,uponstimulationan
increased fraction of BXD2 T cells produce IL-17. Humoral
responses are strongly augmented in these mice [35]. They
spontaneously develop germinal centers (GC) in the spleen
whereIL-17+ TcellscolocalizewithIL-17R+ Bcells[34].The
importance of IL-17 in this process was demonstrated when
B6 and predisease BXD2 mice were infected with an IL-17-
coding adenovirus that increased IL-17 levels and induced
the formation of germinal centers in both mouse strains.
Concordantly, formation of GC diminished and production
of anti-DNA and anti-histone antibodies was abrogated in
BXD2 IL-17R deﬁcient mice [34]. This supports the concept
that IL-17 can provide help to B cells.
4. Ampliﬁcation of the IL-17 Response inSLE
IL-17 is the prototypical cytokine of a CD4 T cell eﬀector
subset known as TH17 cells [7]. TH17 cells are generated
when na¨ ıve CD4 T cells are primed in the presence of
TGF-β and certain inﬂammatory cytokines (i.e., IL-21, IL-
6, and IL-23) [36–38]. Patients with SLE have a higher
frequency of IL-17-producing T cells [21, 22, 25]. It is
thus assumed that the generation of TH17 cells is favored
in SLE patients. Nevertheless, this has not been directly
addressed in any study. Moreover, cells diﬀerent than CD4
T cells are important sources of IL-17 and particularly in
SLE, DN T cells are important producers of this cytokine
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From a theoretical point of view, the SLE environment
is ideal for the generation of TH17 cells. T cells from
patientswithSLEproduceabnormallylowlevelsofIL-2 [39],
a cytokine able to prevent the generation of TH17 cells
and favor that of regulatory T cells [40, 41]. Moreover,
production of the inﬂammatory cytokines IL-6 and IL-21 is
enhanced in cells derived from patients with SLE [42, 43].
Plasmacytoid dendritic cells can induce the conversion of
CD4 T cells into TH17 cells after stimulation through TLR7
[44]. In patients with SLE, who have circulating immune
complexes that contain nucleic acids, this could represent
an important mechanism for the ampliﬁcation of the TH17
response (Figure 1).
In summary, IL-17 production is increased in patients
with SLE. Elevated IL-17 levels probably contribute to the
recruitmentandactivationofimmunecells(e.g.,neutrophils
and T cells) to target organs and thus amplify an ensuing
immune response. The immune environment in patients
with SLE is ideally suited for the generation of IL-17-
producing T cells. Produced IL-17 probably has broad eﬀects
on the immune system that include B cell stimulation [24].
The precise pathways through which IL-17 contributes to
SLE pathology will need to be identiﬁed in future work.
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